Food and Drug Administration, HHS Pt. 556

(4) Dimetridazole; 556.70 Bacitracin. (5) Ipronidazole; 556.100 Carbadox. (6) Other nitroimidazoles; 556.110 Carbomycin. (7) Furazolidone. 556.113 Ceftiofur. 556.115 Cephapirin. (8) Nitrofurazone. 556.118 Chloramine-T. (9) Sulfonamide drugs in lactating 556.120 Chlorhexidine. dairy cattle (except approved use of 556.150 . sulfadimethoxine, 556.160 Clopidol. sulfabromomethazine, and 556.163 Clorsulon. sulfaethoxypyridazine); 556.165 Cloxacillin. (10) Fluoroquinolones; and 556.167 Colistimethate. (11) Glycopeptides. 556.169 Danofloxacin. 556.170 Decoquinate. (12) Phenylbutazone in female dairy 556.180 Dichlorvos. cattle 20 months of age or older. 556.185 Diclazuril. (13) Cephalosporins (not including 556.200 . cephapirin) in cattle, swine, chickens, 556.225 Doramectin. or turkeys: 556.226 Enrofloxacin. (i) For disease prevention purposes; 556.227 Eprinomectin. (ii) At unapproved doses, frequencies, 556.230 . durations, or routes of administration; 556.240 Estradiol and related esters. 556.260 Ethopabate. or 556.273 Famphur. (iii) If the drug is not approved for 556.275 Fenbendazole. that species and production class. 556.277 Fenprostalene. (b) The following drugs, families of 556.283 . drugs, and substances are prohibited 556.286 Flunixin. for extralabel animal and human drug 556.292 Gamithromycin. uses in nonfood-producing animals: 556.300 sulfate. 556.304 Gonadotropin. [Reserved] 556.308 Halofuginone hydrobromide. (c) [Reserved] 556.310 Haloxon. (d) The following drugs, or classes of 556.330 . drugs, that are approved for treating or 556.344 Ivermectin. preventing influenza A, are prohibited 556.346 Laidlomycin. from extralabel use in chickens, tur- 556.347 Lasalocid. keys, and ducks: 556.350 Levamisole hydrochloride. (1) Adamantanes. 556.360 . 556.375 Maduramicin ammonium. (2) Neuraminidase inhibitors. 556.380 Melengestrol acetate. [62 FR 27947, May 22, 1997, as amended at 67 556.410 Metoserpate hydrochloride. FR 5471, Feb. 6, 2002; 68 FR 9530, Feb. 28, 2003; 556.420 Monensin. 68 FR 14134, Mar. 24, 2003; 71 FR 14377, Mar. 556.425 Morantel tartrate. 22, 2006; 77 FR 745, Jan. 6, 2012] 556.426 Moxidectin. 556.428 Narasin. 556.430 . PART 556—TOLERANCES FOR RESI- 556.440 Nequinate. DUES OF NEW ANIMAL DRUGS IN 556.445 Nicarbazin. FOOD 556.460 Novobiocin. 556.470 Nystatin. Subpart A—General Provisions 556.480 . 556.490 Ormetoprim. Sec. 556.495 Oxfendazole. 556.1 General considerations; tolerances for 556.500 . residues of new animal drugs in food. 556.510 Penicillin. 556.513 Piperazine. Subpart B—Specific Tolerances for 556.515 Pirlimycin. Residues of New Animal Drugs 556.540 Progesterone. 556.560 Pyrantel tartrate. 556.34 Albendazole. 556.570 Ractopamine. 556.36 Altrenogest. 556.580 Robenidine hydrochloride. 556.38 Amoxicillin. 556.592 Salinomycin. 556.40 Ampicillin. 556.597 Semduramicin. 556.50 Amprolium. 556.600 . 556.52 . 556.610 . 556.60 Arsenic. 556.620 Sulfabromomethazine sodium.

353

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00363 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB § 556.1 21 CFR Ch. I (4–1–15 Edition)

556.625 Sodium sulfachloropyrazine animal—in which case the accepted monohydrate. method of analysis shall be published 556.630 Sulfachlorpyridazine. or cited, if previously published and 556.640 Sulfadimethoxine. 556.650 Sulfaethoxypyridazine. available elsewhere, in this part; or 556.660 Sulfamerazine. (4) It may or may not be possible to 556.670 Sulfamethazine. determine whether finite residues will 556.685 Sulfaquinoxaline. be incurred but there is no reasonable 556.690 Sulfathiazole. expectation that they may be present— 556.700 Sulfomyxin. 556.710 Testosterone propionate. in which case the establishment of a 556.720 . tolerance is not required; or 556.730 Thiabendazole. (5) The drug is such that it may be 556.732 . metabolized and/or assimilated in such 556.733 Tildipirosin. form that any possible residue would 556.735 Tilmicosin. be indistinguishable from normal tis- 556.739 Trenbolone. 556.740 . sue constituents—in which case the es- 556.741 Tripelennamine. tablishment of a tolerance is not re- 556.745 Tulathromycin. quired. 556.748 Tylvalosin. (b) No tolerance established pursuant 556.750 . to paragraph (a)(1) of this section will 556.760 Zeranol. 556.765 Zilpaterol. be set at any level higher than that re- 556.770 Zoalene. flected by the permitted use of the drug. AUTHORITY: 21 U.S.C. 342, 360b, 371. (c) Any tolerance required pursuant SOURCE: 40 FR 13942, Mar. 27, 1975, unless to this section will, in addition to the otherwise noted. toxicological considerations, be condi- tioned on the availability of a prac- Subpart A—General Provisions ticable analytical method to determine the quantity of residue. Such method § 556.1 General considerations; toler- must be sensitive to and reliable at the ances for residues of new animal drugs in food. established tolerance level or, in cer- tain instances, may be sensitive at a (a) Tolerances established in this higher level where such level is also part are based upon residues of drugs in deemed satisfactory and safe in light of edible products of food-producing ani- the toxicity of the drug residue and of mals treated with such drugs. Consid- the unlikelihood of such residue’s ex- eration of an appropriate tolerance for ceeding the tolerance. a drug shall result in a conclusion ei- ther that: (1) Finite residues will be present in Subpart B—Specific Tolerances for the edible products—in which case a fi- Residues of New Animal Drugs nite tolerance is required; or (2) It is not possible to determine § 556.34 Albendazole. whether finite residues will be incurred (a) Acceptable daily intake (ADI). The but there is reasonable expectation ADI for total residues of albendazole is that they may be present—in which 5 micrograms per kilogram of body case a tolerance for negligible residue weight per day. is required; or (b) Tolerances. The tolerances for (3) The drug induces cancer when in- albendazole 2-aminosulfone (marker gested by man or animal or, after tests residue) are: which are appropriate for the evalua- (1) —(i) : 0.2 tion of the safety of such drug, has Cattle Liver (target tissue) parts per million (ppm). been shown to induce cancer in man or animal; however, such drug will not ad- (ii) Muscle: 0.05 ppm. versely affect the animals for which it (2) Sheep—(i) Liver (target tissue): 0.25 is intended, and no residue of such drug ppm. will be found by prescribed methods of (ii) Muscle: 0.05 ppm. analysis in any edible portion of such (3) Goat—(i) Liver (target tissue): 0.25 animals after slaughter or in any food ppm. yielded by or derived from the living (ii) [Reserved]

354

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00364 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Food and Drug Administration, HHS § 556.113

(c) Related conditions of use. See (2) 0.5 part per million in uncooked § 520.45 of this chapter. muscle. [64 FR 1504, Jan. 11, 1999, as amended at 73 [40 FR 13942, Mar. 27, 1975, as amended at 50 FR 11027, Feb. 29, 2008] FR 18472, May 1, 1985]

§ 556.36 Altrenogest. § 556.52 Apramycin. (a) Acceptable Daily Intake (ADI). The A tolerance of 0.1 part per million is ADI for total residues of altrenogest is established for parent apramycin 0.04 micrograms per kilogram of body (marker residue) in kidney (target tis- sue) of swine. The acceptable daily in- weight per day. take (ADI) for total residues of (b) Tolerances—(1) Swine—(i) Liver (the apramycin is 25 micrograms per kilo- target tissue). The tolerance for gram of body weight per day. altrenogest (the marker residue) is 4 parts per billion (ppb). [62 FR 40933, July 31, 1997] (ii) Muscle. The tolerance for § 556.60 Arsenic. altrenogest (the marker residue) is 1 ppb. (a) [Reserved] (2) [Reserved] (b) Tolerances. The tolerances for total residue of combined arsenic (cal- [68 FR 62007, Oct. 31, 2003] culated as As) are: (1) Turkeys—(i) Muscle and eggs: 0.5 § 556.38 Amoxicillin. parts per million (ppm). A tolerance of 0.01 part per million is (ii) Other edible tissues: 2 ppm. established for negligible residues of (2) [Reserved] amoxicillin in milk and in the (c) Related conditions of use. See uncooked edible tissues of cattle. § 558.369 of this chapter. [79 FR 10979, Feb. 27, 2014] [49 FR 45422, Nov. 16, 1984] § 556.70 Bacitracin. § 556.40 Ampicillin. (a) Acceptable daily intake (ADI). The A tolerance of 0.01 p/m is established ADI for total residues of bacitracin is for negligible residues of ampicillin in 0.05 milligram per kilogram of body the uncooked edible tissues of swine weight per day. and cattle and in milk. (b) Tolerances. The tolerance for resi- dues of bacitracin from zinc bacitracin § 556.50 Amprolium. or bacitracin methylene disalicylate in Tolerances are established as follows uncooked edible tissues of cattle, for residues of amprolium (1-(4-amino- swine, chickens, turkeys, pheasants, 2-n- propyl-5-pyrimidinylmethyl)-2- and quail, and in milk and eggs is 0.5 picolinium chloride hydrochloride): part per million. (a) In the edible tissues and in eggs of [65 FR 70791, Nov. 28, 2000] chickens and turkeys: (1) 1 part per million in uncooked § 556.100 Carbadox. liver and kidney. A tolerance of 30 parts per billion is (2) 0.5 part per million in uncooked established for residues of quinoxaline- muscle tissue. 2-carboxylic acid (marker residue) in (3) In eggs: liver (target tissue) of swine. (i) 8 parts per million in egg yolks. [63 FR 13337, Mar. 19, 1998] (ii) 4 parts per million in whole eggs. (b) In the edible tissues of calves: § 556.110 Carbomycin. (1) 2.0 parts per million in uncooked A tolerance of zero is established for fat. residues of carbomycin in the uncooked (2) 0.5 part per million in uncooked edible tissues of chickens. muscle tissue, liver, and kidney. (c) In the edible tissues of pheasants: § 556.113 Ceftiofur. (1) 1 part per million in uncooked (a) Acceptable daily intake and accept- liver. able single-dose intake—(1) Acceptable

355

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00365 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB § 556.115 21 CFR Ch. I (4–1–15 Edition)

daily intake (ADI). The ADI for total § 556.120 Chlorhexidine. residues of ceftiofur is 30 micrograms A tolerance of zero is established for per kilogram of body weight per day. residues of chlorhexidine in the (2) Acceptable single-dose intake uncooked edible tissues of calves. (ASDI). The ASDI total residues of ceftiofur is 0.830 milligrams per kilo- § 556.150 Chlortetracycline. gram of body weight. The ASDI is the (a) Acceptable daily intake (ADI). The amount of total residues of ceftiofur ADI for total residues of that may safely be consumed in a sin- including chlortetracycline, oxytetra- gle meal. The ASDI is used to derive cycline, and tetracycline is 25 the tolerance for residues of micrograms per kilogram of body desfuroylceftiofur at the injection site. weight per day. (b) Tolerances—(1) Poultry, and sheep. (b) Tolerances. (1) Tolerances are es- A tolerance for residues of ceftiofur in tablished for the sum of tetracycline edible tissue is not required. residues in tissues of beef cattle, non- (2) Swine. The tolerances for lactating dairy cows, calves, swine, desfuroylceftiofur (marker residue) sheep, chickens, turkeys, and ducks, of are: 2 parts per million (ppm) in muscle, 6 (i) Kidney (target tissue). 0.25 parts per ppm in liver, and 12 ppm in fat and kid- million (ppm). ney. (ii)Liver. 3 ppm. (2) A tolerance is established for resi- (iii) Muscle. 2 ppm. dues of chlortetracycline in eggs of 0.4 ppm. (3) Cattle. The tolerances for desfuroylceftiofur (marker residue) [63 FR 52158, Sept. 30, 1998, as amended at 63 are: FR 57246, Oct. 27, 1998] (i) Kidney (target tissue). 0.4 ppm. § 556.160 Clopidol. (ii) Liver. 2 ppm. (iii)Muscle. 1 ppm. Tolerances for residues of clopidol (3,5-dichloro-2,6-dimethyl-4-pyridinol) (iv) Milk. 0.1 ppm. in food are established as follows: [63 FR 53579, Oct. 6, 1998, as amended at 68 FR (a) In cereal grains, vegetables, and 60296, Oct. 22, 2003; 69 FR 43892, July 23, 2004; fruits: 0.2 part per million. 71 FR 39546, July 13, 2006] (b) In chickens and turkeys: (1) 15 parts per million in uncooked § 556.115 Cephapirin. liver and kidney. A tolerance of 0.02 parts per million (2) 5 parts per million in uncooked (ppm) is established for residues of muscle. cephapirin in the milk and 0.1 ppm in (c) In cattle, sheep, and goats: the uncooked edible tissues of dairy (1) 3 parts per million in uncooked cattle. kidney. (2) 1.5 parts per million in uncooked [40 FR 57454, Dec. 10, 1975] liver. (3) 0.2 part per million in uncooked § 556.118 Chloramine-T. muscle. (a) Acceptable Daily Intake (ADI). The (d) In swine: 0.2 part per million in ADI for total residues of chloramine-T uncooked edible tissues. is 5 micrograms per kilogram of body (e) In milk: 0.02 part per million (neg- weight per day. ligible residue). (b) Tolerances—(1) Fish—(i) Muscle/ skin (target tissue). The tolerance for § 556.163 Clorsulon. para-toluenesulfonamide (marker res- (a) Acceptable daily intake (ADI). The idue) is 0.90 parts per million. ADI for total residues of clorsulon is 8 (ii) [Reserved] micrograms per kilogram of body (2) [Reserved] weight per day. (b) —(1) —(i) (c) Related conditions of use. See Tolerances Cattle Kidney (the target tissue). The tolerance for par- § 529.382 of this chapter. ent clorsulon (the marker residue) is [79 FR 37621, July 2, 2014] 1.0 part per million.

356

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00366 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Food and Drug Administration, HHS § 556.226

(ii) Muscle. The tolerance for parent § 556.185 Diclazuril. clorsulon (the marker residue) is 0.1 (a) Acceptable daily intake (ADI). The part per million. ADI for total residues of diclazuril is 25 (2) [Reserved] micrograms per kilogram of body [66 FR 35544, July 6, 2001] weight per day. (b) Tolerances—(1) Chickens—(i) Liver. § 556.165 Cloxacillin. The tolerance for parent diclazuril (the A tolerance of 0.01 part per million is marker residue) is 3 parts per million established for negligible residues of (ppm). cloxacillin in the uncooked edible tis- (ii) Muscle. The tolerance for parent sues of cattle and in milk. diclazuril (the marker residue) is 0.5 ppm. [40 FR 28792, July 9, 1975] (iii) Skin/fat. The tolerance for parent diclazuril (the marker residue) is 1 § 556.167 Colistimethate. ppm. A tolerance for residues of (2) Turkeys—(i) Liver. The tolerance colistimethate in the edible tissues of for parent diclazuril (the marker res- chickens is not required. idue) is 3 ppm. (ii) Muscle. The tolerance for parent [63 FR 13123, Mar. 18, 1998] diclazuril (the marker residue) is 0.5 ppm. § 556.169 Danofloxacin. (iii) Skin/fat. The tolerance for parent (a) Acceptable daily intake (ADI). The diclazuril (the marker residue) is 1 ADI for total residues of danofloxacin ppm. is 2.4 micrograms per kilogram of body weight per day. [64 FR 35923, July 2, 1999. Redesignated and amended at 66 FR 62917, Dec. 4, 2001] (b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for par- § 556.200 Dihydrostreptomycin. ent danofloxacin (the marker residue) is 0.2 part per million (ppm). Tolerances are established for resi- (ii) Muscle. The tolerance for parent dues of dihydrostreptomycin in danofloxacin (the marker residue) is 0.2 uncooked, edible tissues of cattle and swine of 2.0 parts per million (ppm) in ppm. kidney and 0.5 ppm in other tissues, (2) [Reserved] and 0.125 ppm in milk. [67 FR 78973, Dec. 27, 2002] [59 FR 41977, Aug. 16, 1994]

§ 556.170 Decoquinate. § 556.225 Doramectin. (a) Acceptable daily intake (ADI). The (a) Acceptable daily intake (ADI). The ADI for total residues of decoquinate is ADI for total residues of doramectin is 75 micrograms per kilogram of body 0.75 microgram per kilogram of body weight per day. weight per day. (b) Tolerances. Tolerances are estab- (b) Tolerances—(1) Cattle. A tolerance lished for residues of decoquinate in of 100 parts per billion is established the uncooked, edible tissues of chick- for parent doramectin (marker residue) ens, cattle, and goats as follows: in liver (target tissue) and of 30 parts (1) 1 part per million (ppm) in skel- per billion for parent doramectin in etal muscle. muscle. (2) 2 ppm in other tissues. (2) Swine. A tolerance is established for parent doramectin (marker residue) [64 FR 10103, Mar. 2, 1999] in liver (target tissue) of 160 parts per § 556.180 Dichlorvos. billion. A tolerance of 0.1 part per million is [63 FR 68184, Dec. 10, 1998] established for negligible residues of dichlorvos (2,2-dichlorovinyl dimethyl § 556.226 Enrofloxacin. phosphate) in the edible tissues of (a) Acceptable daily intake (ADI). The swine. ADI for total residues of enrofloxacin

357

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00367 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB § 556.227 21 CFR Ch. I (4–1–15 Edition)

is 3 micrograms per kilogram of body (3) 360 parts per trillion for kidney. weight per day. (4) 240 parts per trillion for liver. (b) Tolerances. The tolerances for (b) [Reserved] enrofloxacin are: (1) Cattle—(i) Liver (target tissue). 0.1 [49 FR 13873, Apr. 9, 1984, as amended at 56 part per million (ppm) desethylene FR 67175, Dec. 30, 1991; 76 FR 16291, Mar. 23, ciprofloxacin (the marker residue). 2011] (ii) [Reserved] § 556.260 Ethopabate. (2) Swine—(i) Liver (target tissue). 0.5 ppm enrofloxacin (the marker residue). Tolerance for residues of ethopabate (ii) [Reserved] converted to metaphenetidine are es- (c) Related conditions of use. See tablished in the edible tissues of chick- § 522.812 of this chapter. ens as follows: [73 FR 21819, Apr. 23, 2008] (a) 1.5 parts per million in uncooked liver and kidney. § 556.227 Eprinomectin. (b) 0.5 part per million in uncooked (a) Acceptable daily intake (ADI). The muscle. ADI for total residues of eprinomectin is 10 micrograms per kilogram of body § 556.273 Famphur. weight per day. Tolerances are established for resi- (b) Tolerances. The tolerances for dues of famphur including its oxygen eprinomectin B1a (marker residue) are: analog in or on meat, fat, or meat by- (1) Cattle—(i) Liver (target tissue): 1.5 products of cattle at 0.1 part per mil- parts per million. lion. (ii) Muscle: 100 parts per billion (ppb). (iii) Milk: 12 ppb. [62 FR 55161, Oct. 23, 1997] (2) [Reserved] (c) Related conditions of use. See § 556.275 Fenbendazole. §§ 522.814 and 524.814 of this chapter. (a) Acceptable daily intake (ADI). The ADI for total residues of fenbendazole [63 FR 59715, Nov. 5, 1998, as amended at 76 FR 72619, Nov. 25, 2011] is 40 micrograms per kilogram of body weight per day. § 556.230 Erythromycin. (b) Tolerances—(1) Cattle—(i) Liver Tolerances for residues of erythro- (the target tissue). The tolerance for par- mycin in food are established as fol- ent fenbendazole (the marker residue) lows: is 0.8 part per million (ppm). (a) 0.1 part per million in uncooked (ii) Muscle. The tolerance for parent edible tissues of beef cattle and swine. fenbendazole (the marker residue) is 0.4 (b) Zero in milk. ppm. (c) 0.025 part per million in uncooked (iii) Milk. The tolerance for eggs. fenbendazole sulfoxide metabolite (the (d) 0.125 part per million (negligible marker residue in cattle milk) is 0.6 residue) in uncooked edible tissues of ppm. chickens and turkeys. (2) Swine—(i) Liver (the target tissue). The tolerance for parent fenbendazole [40 FR 13942, Mar. 27, 1975, as amended at 58 FR 43795, Aug. 18, 1993] (the marker residue) is 6 ppm. (ii) Muscle. The tolerance for parent § 556.240 Estradiol and related esters. fenbendazole (the marker residue) is 2 No residues of estradiol, resulting ppm. from the use of estradiol or any of the (3) Turkeys—(i) Liver (the target tis- related esters, are permitted in excess sue). The tolerance for fenbendazole of the following increments above the sulfone (the marker residue) is 6 ppm. concentrations of estradiol naturally (ii) Muscle. The tolerance for present in untreated animals: fenbendazole sulfone (the marker res- (a) In uncooked edible tissues of heif- idue) is 2 ppm. ers, steers, and calves: (4) Goats—(i) Liver (the target tissue). (1) 120 parts per trillion for muscle. The tolerance for parent fenbendazole (2) 480 parts per trillion for fat. (the marker residue) is 0.8 ppm.

358

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00368 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Food and Drug Administration, HHS § 556.300

(ii) Muscle. The tolerance for parent § 556.286 Flunixin. fenbendazole (the marker residue) is 0.4 (a) Acceptable daily intake (ADI). The ppm. ADI for total residues of flunixin is 0.72 [65 FR 20733, Apr. 18, 2000, as amended at 65 micrograms per kilogram of body FR 41588, July 6, 2000; 65 FR 50914, Aug. 22, weight per day. 2000] (b) Tolerances—(1) Cattle. The toler- ance for flunixin free acid (the marker § 556.277 Fenprostalene. residue) is: A tolerance for marker residue of (i) Liver (the target tissue). 125 parts fenprostalene in cattle is not needed. per billion (ppb). The safe concentrations for the total (ii) Muscle. 25 ppb. residues of fenprostalene in the (iii) Milk: 2 ppb 5-hydroxy flunixin. uncooked edible tissues of cattle are 10 (2) Swine. The tolerance for flunixin parts per billion in muscle, 20 parts per free acid (the marker residue) is: billion in liver, 30 parts per billion in kidney, 40 parts per billion in fat, and (i) Liver (the target tissue). 30 ppb. 100 parts per billion in the injection (ii) Muscle. 25 ppb. site. As used in this section ‘‘toler- (c) Related conditions of use. See ance’’ refers to a concentration of a §§ 522.956 and 522.970 of this chapter. marker residue in the target tissue se- [63 FR 38750, July 20, 1998, as amended at 69 lected to monitor for total residues of FR 60309, Oct. 8, 2004; 70 FR 70999, Nov. 25, the drug in the target animal, and 2005; 76 FR 16291, Mar. 23, 2011] ‘‘safe concentrations’’ refer to the con- centrations of total residues considered § 556.292 Gamithromycin. safe in edible tissues. (a) Acceptable Daily Intake (ADI). The [49 FR 26716, June 29, 1984] ADI for total residues of gamithromycin is 10 micrograms per § 556.283 Florfenicol. kilogram of body weight per day. (a) Acceptable daily intake (ADI). The (b) Tolerances. The tolerances for ADI for total residues of florfenicol is gamithromycin (the marker residue) 10 micrograms per kilogram of body are: weight per day. (1) Cattle—(i) Liver (the target tissue): (b) Tolerances—(1) Cattle—(i) Liver 500 parts per billion (ppb). (the target tissue). The tolerance for (ii) Muscle. 150 ppb. florfenicol amine (the marker residue) (2) [Reserved] is 3.7 parts per million (ppm). (c) Related conditions of use. See (ii) Muscle. The tolerance for § 522.1014 of this chapter. florfenicol amine (the marker residue) [76 FR 57907, Sept. 19, 2011] is 0.3 ppm. (2) Swine—(i) Liver (the target tissue). § 556.300 Gentamicin sulfate. The tolerance for parent florfenicol (the marker residue) is 2.5 ppm. (a) A tolerance of 0.1 part per million is established for negligible residues of (ii) Muscle. The tolerance for parent gentamicin sulfate in the uncooked ed- florfenicol (the marker residue) is 0.2 ible tissues of chickens and turkeys. ppm. (b) Tolerances are established for (3) Catfish. The tolerance for total residues of gentamicin in edible florfenicol amine (the marker residue) tissues of swine as follows: 0.1 part per in muscle (the target tissue) is 1 ppm. million in muscle, 0.3 part per million (4) Salmonids. The tolerance for in liver, and 0.4 part per million in fat florfenicol amine (the marker residue) and kidney. A microbiological deter- in muscle/skin (the target tissues) is 1 minative procedure and an HPLC con- ppm. firmatory procedure for gentamicin (c) Related conditions of use. See have been developed to assay §§ 520.955, 522.955, 522.956, and 558.261 of gentamicin in kidney at 0.4 ppm. Since this chapter. residues of gentamicin as the parent [76 FR 16291, Mar. 23, 2011] compound and total residues are equal,

359

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00369 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB § 556.304 21 CFR Ch. I (4–1–15 Edition)

the marker (parent drug) residue con- coumarin bis(2-chloroethyl) phosphate) centration of 0.4 ppm in kidney cor- in the edible tissues of cattle. responds to 0.4 ppm of total residue. [40 FR 13942, Mar. 27, 1975, as amended at 45 [48 FR 791, Jan. 7, 1983, as amended at 61 FR FR 10333, Feb. 15, 1980] 24441, May 15, 1996] § 556.330 Hygromycin B. § 556.304 Gonadotropin. A tolerance of zero is established for residues of hygromycin B in or on eggs (a) Acceptable daily intake (ADI). The and the uncooked edible tissues of ADI for residues of total gonadotropins swine and poultry. (human chorionic gonadotropin and pregnant mare serum gonadotropin) is § 556.344 Ivermectin. 42.25 I.U. per kilogram of body weight (a) Acceptable Daily Intake (ADI). The per day. ADI for total residues of ivermectin is (b) Tolerances. A tolerance for resi- 5 micrograms per kilogram of body dues of gonadotropin in uncooked edi- weight per day. ble tissues of cattle or of fish is not re- (b) Tolerances—(1) Liver. A tolerance quired. is established for 22,23- dihydroavermectin B a (marker res- [64 FR 48545, Sept. 7, 1999] 1 idue) in liver (target tissue) as follows: § 556.308 Halofuginone hydrobromide. (i) Cattle. 1.6 parts per million. (ii) Swine. 20 parts per billion. The marker residue selected to mon- (iii) Sheep. 30 parts per billion. itor for total residues of halofuginone (iv) Reindeer. 15 parts per billion. hydrobromide in broilers and turkeys (v) American bison. 15 parts per bil- is parent halofuginone hydrobromide lion. and the target tissue selected is liver. (2) Muscle. Muscle residues are not in- A tolerance is established in broilers of dicative of the safety of other edible 0.16 part per million and in turkeys of tissues. A tolerance is established for 0.13 part per million for parent 22,23-dihydroavermectin B1a (marker halofuginone hydrobromide in liver. residue) in muscle as follows: These marker residue concentrations (i) Swine. 20 parts per billion. in liver correspond to total residue (ii) Cattle. 650 parts per billion. concentrations of 0.3 part per million (c) Related conditions of use. See §§ 520.1192, 520.1195, 520.1197, 522.1192, in liver. The safe concentrations for 522.1193, 524.1193, and 558.300 of this total residues of halofuginone chapter. hydrobromide in the uncooked edible tissues of broilers and turkeys are 0.1 [63 FR 54352, Oct. 9, 1998, as amended at 64 FR part per million in muscle, 0.3 part per 26671, May 17, 1999; 79 FR 64117, Oct. 28, 2014] million in liver, and 0.2 part per mil- § 556.346 Laidlomycin. lion in skin with adhering fat. As used in this section, ‘‘tolerance’’ refers to a (a) Acceptable daily intake (ADI). The ADI for total residues of laidlomycin is concentration of a marker residue in 7.5 micrograms per kilogram of body the target tissue selected to monitor weight per day. for total residues of the drug in the (b) Tolerance. The tolerance for par- target animal, and ‘‘safe concentra- ent laidlomycin (the marker residue) tions’’ refers to the concentrations of in the liver (the target tissue) of cattle total residues considered safe in edible is 0.2 part per million (ppm). tissues. [68 FR 42590, July 18, 2003] [54 FR 28052, July 5, 1989, as amended at 56 FR 8711, Mar. 1, 1991; 57 FR 21209, May 19, § 556.347 Lasalocid. 1992] (a) Acceptable daily intake (ADI). The ADI for total residues of lasalocid is 10 § 556.310 Haloxon. micrograms per kilogram of body A tolerance of 0.1 part per million is weight per day. established for negligible residues of (b) Tolerances—(1) Cattle. The toler- haloxon (3-chloro-7-hydroxy-4-methyl- ance for parent lasalocid (the marker

360

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00370 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Food and Drug Administration, HHS § 556.426

residue) in liver (the target tissue) is parts per million in liver; 0.48 parts per 0.7 part per million (ppm). million in skin; and 0.48 parts per mil- (2) Chickens—(i) Skin with adhering fat lion in fat. A safe concentration refers (the target tissue). The tolerance for par- to the total residue concentration con- ent lasalocid (the marker residue) is 1.2 sidered safe in edible tissues. ppm. (ii) Liver. The tolerance for parent [54 FR 5229, Feb. 2, 1989] lasalocid (the marker residue) is 0.4 § 556.380 Melengestrol acetate. ppm. (3) Turkeys—(i) Liver (the target tis- A tolerance of 25 parts per billion is sue). The tolerance for parent lasalocid established for residues of the parent (the marker residue) is 0.4 ppm. compound, melengestrol acetate, in fat (ii) Skin with adhering fat. The toler- of cattle. ance for parent lasalocid (the marker [59 FR 41241, Aug. 11, 1994] residue) is 0.4 ppm. (4) Rabbits. The tolerance for parent § 556.410 Metoserpate hydrochloride. lasalocid (the marker residue) in liver A tolerance of 0.02 part per million is (the target tissue) is 0.7 ppm. established for negligible residues of (5) Sheep. The tolerance for parent metoserpate hydrochloride (methyl-o- lasalocid (the marker residue) in liver methyl-18-epireserpate hydrochloride) (the target tissue) is 1.0 ppm. in uncooked edible tissues of chickens. [66 FR 19854, Apr. 18, 2001] § 556.420 Monensin. § 556.350 Levamisole hydrochloride. (a) Acceptable daily intake (ADI). The A tolerance of 0.1 part per million is ADI for total residues of monensin is established for negligible residues of 12.5 micrograms per kilogram of body levamisole hydrochloride in the edible weight per day. tissues of cattle, sheep, and swine. (b) Tolerances. The tolerances for res- idues of monensin are: § 556.360 Lincomycin. (1) Cattle—(i) Liver. 0.10 part per mil- (a) Acceptable daily intake (ADI). The lion (ppm). ADI for total residues of lincomycin is (ii) Muscle, kidney, and fat. 0.05 ppm. 25 micrograms per kilogram of body (iii) Milk. Not required. weight per day. (2) Goats—(i) Edible tissues. 0.05 ppm. (b) Chickens. A tolerance for residues (ii) [Reserved] of lincomycin in chickens is not re- (3) Chickens, turkeys, and quail. A tol- quired. erance for residues of monensin in (c) Swine. Tolerances for lincomycin chickens, turkeys, and quail is not re- of 0.6 part per million in liver and 0.1 quired. part per million in muscle are estab- (c) Related conditions of use. See lished. §§ 520.1448 and 558.355 of this chapter. [64 FR 13342, Mar. 18, 1999] [64 FR 5159, Feb. 3, 1999, as amended at 69 FR 68783, Nov. 26, 2004; 72 FR 56897, Oct. 5, 2007] § 556.375 Maduramicin ammonium. A tolerance is established for resi- § 556.425 Morantel tartrate. dues of maduramicin ammonium in A tolerance of 0.7 part per million is chickens as follows: established for N-methyl-1,3- (a) A tolerance for maduramicin am- propanediamine (MAPA, marker res- monium (marker residue) in chickens idue) in the liver (target tissue) of cat- is 0.38 parts per million in fat (target tle and goats. A tolerance for residues tissue). A tolerance refers to the con- of morantel tartrate in milk is not re- centration of marker residues in the quired. target tissue used to monitor for total drug residues in the target animals. [59 FR 17922, Apr. 15, 1994] (b) The safe concentrations for total maduramicin ammonium residues in § 556.426 Moxidectin. uncooked edible chicken tissues are: (a) Acceptable daily intake (ADI). The 0.24 parts per million in muscle; 0.72 ADI for total residues of moxidectin is

361

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00371 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB § 556.428 21 CFR Ch. I (4–1–15 Edition)

4 micrograms per kilogram of body (3) Milk. A tolerance is established weight per day. for residues of parent neomycin of 0.15 (b) Tolerances—(1) Cattle—(i) Fat (the ppm. target tissue). The tolerance for parent [64 FR 31498, June 11, 1999] moxidectin (the marker residue) is 900 parts per billion (ppb). § 556.440 Nequinate. (ii) Liver. The tolerance for parent moxidectin (the marker residue) is 200 A tolerance of 0.1 part per million is ppb. established for negligible residues of (iii) Muscle. The tolerance for parent nequinate in the uncooked edible tis- moxidectin (the marker residue) is 50 sues of chickens. ppb. § 556.445 Nicarbazin. (iv) Milk. The tolerance for parent moxidectin (the marker residue) is 40 A tolerance of 4 parts per million is ppb. established for residues of nicarbazin in (2) Sheep—(i) Fat (the target tissue). uncooked chicken muscle, liver, skin, The tolerance for parent moxidectin and kidney. (the marker residue) is 900 parts per [42 FR 56729, Oct. 28, 1977] billion (ppb). (ii) Liver. The tolerance for parent § 556.460 Novobiocin. moxidectin (the marker residue) is 200 Tolerances for residues of novobiocin ppb. are established at 0.1 part per million (iii) Muscle. The tolerance for parent in milk from dairy animals and 1 part moxidectin (the marker residue) is 50 per million in the uncooked edible tis- ppb. sues of cattle, chickens, turkeys, and (c) Related conditions of use. See ducks. §§ 520.1454 and 522.1450 of this chapter. [47 FR 18590, Apr. 30, 1982] [65 FR 36617, June 9, 2000, as amended at 65 FR 76930, Dec. 8, 2000; 70 FR 36338, June 23, § 556.470 Nystatin. 2005; 70 FR 76163, Dec. 23, 2005] A tolerance of zero is established for § 556.428 Narasin. residues of nystatin in or on eggs and (a) Acceptable daily intake (ADI). The the uncooked edible tissues of swine ADI for total residues of narasin is 5 and poultry. micrograms per kilogram of body § 556.480 Oleandomycin. weight per day. (b) Tolerances—(1) Chickens (abdominal Tolerances are established for neg- fat). The tolerance for parent narasin ligible residues of oleandomycin in (the marker residue) is 480 parts per uncooked edible tissues of chickens, billion. turkeys, and swine at 0.15 part per mil- (2) [Reserved] lion. [66 FR 23589, May 9, 2001] § 556.490 Ormetoprim. § 556.430 Neomycin. (a) [Reserved] (b) Tolerances. A tolerance of 0.1 part (a) Acceptable daily intake (ADI). The per million (ppm) is established for ADI for total residues of neomycin is 6 negligible residues of ormetoprim in micrograms per kilogram of body uncooked edible tissues of chickens, weight per day. turkeys, ducks, salmonids, catfish, and (b) Tolerances. Tolerances are estab- chukar partridges. lished for residues of parent neomycin in uncooked edible tissues as follows: [64 FR 26672, May 17, 1999] (1) Cattle, swine, sheep, and goats. 7.2 parts per million (ppm) in kidney (tar- § 556.495 Oxfendazole. get tissue) and fat, 3.6 ppm in liver, and Cattle: A tolerance is established for 1.2 ppm in muscle. total oxfendazole residues in edible (2) Turkeys. 7.2 ppm in skin with cattle tissues based on a marker res- adhearing fat, 3.6 ppm in liver, and 1.2 idue concentration of 0.8 part per mil- ppm in muscle. lion (ppm) fenbendazole in the target

362

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00372 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Food and Drug Administration, HHS § 556.570

liver tissue. A fenbendazole concentra- § 556.513 Piperazine. tion of 0.8 ppm in liver corresponds to A tolerance of 0.1 part per million pi- a total safe concentration of perazine base is established for edible oxfendazole residues of 1.7 ppm in liver. tissues of poultry and swine. The safe concentrations of total oxfendazole residues in other uncooked [64 FR 23019, Apr. 29, 1999] edible cattle tissues are: muscle, 0.84 § 556.515 Pirlimycin. ppm; kidney, 2.5 ppm; and fat, 3.3 ppm. A tolerance refers to the concentration (a) Acceptable daily intake (ADI). The of marker residue in the target tissue ADI for total residues of pirlimycin is selected to monitor for total drug res- 0.01 milligrams per kilogram of body idue in the target animal. A safe con- weight per day. centration is the total residue consid- (b) Tolerances—(1) Cattle—(i) Liver ered safe in edible tissue. (the target tissue). The tolerance for par- ent pirlimycin (the marker residue) is [55 FR 46943, Nov. 8, 1990] 0.5 part per million (ppm). (ii) Muscle. The tolerance for parent § 556.500 Oxytetracycline. pirlimycin (the marker residue) is 0.3 (a) Acceptable daily intake (ADI). The ppm. ADI for total tetracycline residues (iii) Milk. The tolerance for parent (chlortetracycline, oxytetracycline, pirlimycin (the marker residue in cat- and tetracycline) is 25 micrograms per tle milk) is 0.4 ppm. kilogram of body weight per day. (2) [Reserved] (b) Beef cattle, dairy cattle, calves, [65 FR 61091, Oct. 16, 2000] swine, sheep, chickens, turkeys, finfish, and lobster. Tolerances are established § 556.540 Progesterone. for the sum of residues of the (a) [Reserved] tetracyclines including chlortetra- (b) Tolerances. Residues of progester- cycline, oxytetracycline, and tetra- one are not permitted in excess of the cycline, in tissues and milk as follows: following increments above the con- (1) 2 parts per million (ppm) in mus- centrations of progesterone naturally cle. present in untreated animals: (2) 6 ppm in liver. (1) Cattle and sheep—(i) Muscle: 5 (3) 12 ppm in fat and kidney. parts per billion (ppb). (4) 0.3 ppm in milk. (ii) Liver: 15 ppb. (iii) Kidney: 30 ppb. [63 FR 57246, Oct. 27, 1998, as amended at 66 (iv) Fat: 30 ppb. FR 46370, Sept. 5, 2001; 69 FR 6557, Feb. 11, (2) [Reserved] 2004] (c) Related conditions of use. See §§ 522.1940 and 529.1940 of this chapter. § 556.510 Penicillin. Tolerances are established for resi- [76 FR 57907, Sept. 19, 2011] dues of penicillin and the salts of peni- § 556.560 Pyrantel tartrate. cillin in food as follows: (a) 0.05 part per million (negligible Tolerances are established for resi- dues of pyrantel tartrate in edible tis- residue) in the uncooked edible tissues sues of swine as follows: of cattle. (a) 10 parts per million in liver and (b) Zero in the uncooked edible tis- kidney. sues of chickens, pheasants, quail, (b) 1 part per million in muscle. swine, and sheep; in eggs; and in milk or in any processed food in which such § 556.570 Ractopamine. milk has been used. (a) Acceptable Daily Intake (ADI). The (c) 0.01 part per million in the ADI for total residues of ractopamine uncooked edible tissues of turkeys. hydrochloride is 1.25 micrograms per [40 FR 13942, Mar. 27, 1975, as amended at 43 kilogram of body weight per day. FR 32749, July 28, 1978] (b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for

363

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00373 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB § 556.580 21 CFR Ch. I (4–1–15 Edition)

ractopamine hydrochloride (the mark- (b) Chickens and turkeys. A tolerance er residue) is 0.09 parts per million of 0.1 part per million (ppm) for neg- (ppm). ligible residues of spectinomycin in (ii) Muscle. The tolerance for uncooked edible tissues of chickens ractopamine hydrochloride (the mark- and turkeys is established. er residue) is 0.03 ppm. (c) Cattle. A tolerance of 4 ppm for (2) Swine—(i) Liver (the target tissue). parent spectinomycin (marker residue) The tolerance for ractopamine hydro- in kidney (target tissue) is established. chloride (the marker residue) is 0.15 A tolerance of 0.25 ppm for parent ppm. spectinomycin in cattle muscle is es- (ii) Muscle. The tolerance for tablished. ractopamine hydrochloride (the mark- er residue) is 0.05 ppm. [63 FR 24107, May 1, 1998; 63 FR 38304, July 16, (3) Turkeys—(i) Liver (the target tis- 1998] sue). The tolerance for ractopamine (the marker residue) is 0.45 ppm. § 556.610 Streptomycin. (ii) Muscle. The tolerance for Tolerances are established for resi- ractopamine (the marker residue) is 0.1 dues of streptomycin in uncooked, edi- ppm. ble tissues of chickens, swine, and [68 FR 54659, Sept. 18, 2003, as amended at 73 calves of 2.0 parts per million (ppm) in FR 72715, Dec. 1, 2008] kidney and 0.5 ppm in other tissues. [58 FR 47211, Sept. 8, 1993] § 556.580 Robenidine hydrochloride. Tolerances are established for resi- § 556.620 Sulfabromomethazine so- dues of robenidine hydrochloride in ed- dium. ible tissues of chickens as follows: Tolerances for residues of (a) 0.2 part per million in skin and sulfabromomethazine sodium in food fat. are established as follows: (b) 0.1 part per million (negligible residue) in edible tissues other than (a) In the uncooked edible tissues of skin and fat. cattle at 0.1 part per million (negligible residue). § 556.592 Salinomycin. (b) In milk at 0.01 part per million (a) Acceptable daily intake (ADI). The (negligible residue). ADI for total residues of salinomycin is [47 FR 30244, July 13, 1982] 0.005 milligram per kilogram of body weight per day. § 556.625 Sodium sulfachloropyrazine (b) [Reserved] monohydrate. [65 FR 70791, Nov. 28, 2000] A tolerance of zero is established for residues of sodium sulfachloropyrazine § 556.597 Semduramicin. monohydrate in the uncooked edible (a) Acceptable daily intake (ADI). The tissues of chickens. ADI for total residues of semduramicin is 180 micrograms per kilogram of body § 556.630 Sulfachlorpyridazine. weight per day. A tolerance of 0.1 part per million is (b) Tolerances—(1) Broiler chickens. established for negligible residues of Tolerances are established for residues sulfachlorpyridazine in uncooked edi- of parent semduramicin in uncooked ble tissues of calves and swine. edible tissues of 400 parts per billion (ppb) in liver and 130 ppb in muscle. § 556.640 Sulfadimethoxine. (2) [Reserved] (a) [Reserved] [64 FR 48296, Sept. 3, 1999] (b) Tolerances. (1) A tolerance of 0.1 part per million (ppm) is established § 556.600 Spectinomycin. for negligible residues of (a) Acceptable daily intake (ADI). The sulfadimethoxine in uncooked edible ADI for total residues of spectinomycin tissues of chickens, turkeys, cattle, is 25 micrograms per kilogram of body ducks, salmonids, catfish, and chukar weight per day. partridges.

364

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00374 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Food and Drug Administration, HHS § 556.733

(2) A tolerance of 0.01 ppm is estab- (a) In uncooked edible tissues of heif- lished for negligible residues of ers: sulfadimethoxine in milk. (1) 0.64 part per billion in muscle. [64 FR 26672, May 17, 1999] (2) 2.6 parts per billion in fat. (3) 1.9 parts per billion in kidney. § 556.650 Sulfaethoxypyridazine. (4) 1.3 parts per billion in liver. Tolerances for residues of (b) [Reserved] sulfaethoxypyridazine in food are es- [52 FR 27683, July 23, 1987] tablished as follows: (a) Zero in the uncooked edible tis- § 556.720 Tetracycline. sues of swine and in milk. (a) Acceptable daily intake (ADI). The (b) 0.1 part per million (negligible ADI for total tetracycline residues residue) in uncooked edible tissues of (chlortetracycline, oxytetracycline, cattle. and tetracycline) is 25 micrograms per kilogram of body weight per day. § 556.660 Sulfamerazine. (b) Tolerances. Tolerances are estab- A tolerance of zero is established for lished for the sum of tetracycline resi- residues of sulfamerazine (N1-[4-meth- dues in tissues of calves, swine, sheep, yl-2-pyrimidinyl]sulfanilamide) in the chickens, and turkeys, of 2 parts per uncooked edible tissues of trout. million (ppm) in muscle, 6 ppm in liver, and 12 ppm in fat and kidney. § 556.670 Sulfamethazine. A tolerance of 0.1 part per million is [63 FR 57246, Oct. 27, 1998] established for negligible residues of § 556.730 Thiabendazole. sulfamethazine in the uncooked edible tissues of chickens, turkeys, cattle, Tolerances are established at 0.1 part and swine. per million for negligible residues of thiabendazole in uncooked edible tis- [47 FR 25323, June 11, 1982] sues of cattle, goats, sheep, pheasants, § 556.685 Sulfaquinoxaline. and swine, and at 0.05 part per million for negligible residues in milk. A tolerance of 0.1 part per million is established for negligible residues of [40 FR 13942, Mar. 27, 1975, as amended at 49 sulfaquinoxaline in the uncooked edi- FR 29958, July 25, 1984] ble tissues of chickens, turkeys, calves, § 556.732 Tiamulin. and cattle. A tolerance of 0.6 part per million is [61 FR 24443, May 15, 1996] established for 8-alpha-hydroxymutilin (marker compound) in liver (target tis- § 556.690 Sulfathiazole. sue) of swine. A tolerance of 0.1 part per million is established for negligible residues of [62 FR 12086, Mar. 14, 1997. Redesignated at 80 sulfathiazole in the uncooked edible FR 13230, Mar. 13, 2015] tissues of swine. § 556.733 Tildipirosin. § 556.700 Sulfomyxin. (a) Acceptable Daily Intake (ADI). The A tolerance of zero is established for ADI for total residues of tildipirosin is residues of sulfomyxin (N-sulfomethyl- 50 micrograms per kilogram of body polymyxin B sodium salt) in uncooked weight per day. edible tissues from chickens and tur- (b) Tolerances. The tolerances for keys. tildipirosin (the marker residue) are: (1) Cattle—(i) Liver (the target tissue): § 556.710 Testosterone propionate. 10 parts per million. No residues of testosterone, resulting (ii) [Reserved] from the use of testosterone propio- (2) [Reserved] nate, are permitted in excess of the fol- (c) Related conditions of use. See lowing increments above the con- § 522.2460 of this chapter. centrations of testosterone naturally [77 FR 39391, July 3, 2012, as amended at 78 present in untreated animals: FR 52854, Aug. 27, 2013]

365

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00375 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB § 556.735 21 CFR Ch. I (4–1–15 Edition)

§ 556.735 Tilmicosin. § 556.741 Tripelennamine. (a) Acceptable daily intake (ADI). The A tolerance of 200 parts per billion ADI for total residues of tilmicosin is (ppb) is established for residues of 25 micrograms per kilogram of body tripelennamine in uncooked edible tis- weight per day. sues of cattle and 20 ppb in milk. (b) Tolerances—(1) Cattle—(i) Liver [62 FR 4164, Jan. 29, 1997] (the target tissue). The tolerance for par- ent tilmicosin (the marker residue) is § 556.745 Tulathromycin. 1.2 parts per million (ppm). (a) Acceptable daily intake (ADI). The (ii) Muscle. The tolerance for parent ADI for total residues of tulathromycin tilmicosin (the marker residue) is 0.1 is 15 micrograms per kilogram of body ppm. weight per day. (2) Swine—(i) Liver (the target tissue). (b) Tolerances—(1) Cattle—(i) Liver The tolerance for parent tilmicosin (the target tissue). The tolerance for CP– (the marker residue) is 7.5 ppm. 60,300 (the marker residue) is 5.5 parts (ii) Muscle. The tolerance for parent per million (ppm). tilmicosin (the marker residue) is 0.1 (ii) [Reserved] ppm. (2) Swine—(i) Kidney (the target tis- (3) Sheep—(i) Liver (the target tissue). sue). The tolerance for CP–60,300 (the The tolerance for parent tilmicosin marker residue) is 15 ppm. (the marker residue) is 1.2 ppm. (ii) [Reserved] (ii) Muscle. The tolerance for parent (c) Related conditions of use. See tilmicosin (the marker residue) is 0.1 § 522.2630 of this chapter. ppm. [70 FR 39918, July 12, 2005] [64 FR 13679, Mar. 22, 1999, as amended at 67 FR 72368, Dec. 5, 2002; 78 FR 52854, Aug. 27, § 556.748 Tylvalosin. 2013] (a) Acceptable Daily Intake (ADI). The ADI for total residues of tylvalosin is § 556.739 Trenbolone. 47.7 micrograms per kilogram of body (a) Acceptable daily intake (ADI). The weight per day. ADI for total residues of trenbolone is (b) Tolerances. A tolerance for 0.4 microgram per kilogram of body tylvalosin in edible tissues of swine is weight per day. not required. (b) Tolerances. A tolerance for total (c) Related conditions of use. See trenbolone residues in uncooked edible § 520.2645 of this chapter. tissues of cattle is not needed. [77 FR 55415, Sept. 10, 2012] [64 FR 18574, Apr. 15, 1999] § 556.750 Virginiamycin. § 556.740 Tylosin. (a) Acceptable daily intake (ADI). The Tolerances are established for resi- ADI for total residues of virginiamycin dues of tylosin in edible products of is 250 micrograms per kilogram of body animals as follows: weight per day. (a) In chickens and turkeys: 0.2 part (b) Tolerances—(1) Swine. Tolerances per million (negligible residue) in are established for residues of uncooked fat, muscle, liver, and kid- virginiamycin in uncooked edible tis- ney. sues of 0.4 part per million (ppm) in (b) In cattle: 0.2 part per million kidney, skin, and fat, 0.3 ppm in liver, (negligible residue) in uncooked fat, and 0.1 ppm in muscle. muscle, liver, and kidney. (2) Broiler chickens and cattle. A toler- (c) In swine: 0.2 part per million (neg- ance for residues of virginiamycin is ligible residue) in uncooked fat, mus- not required. cle, liver, and kidney. [64 FR 48296, Sept. 3, 1999] (d) In milk: 0.05 part per million (neg- ligible residue). § 556.760 Zeranol. (e) In eggs: 0.2 part per million (neg- (a) Acceptable daily intake (ADI). The ligible residue). ADI for total residues of zeranol is

366

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00376 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB Food and Drug Administration, HHS Pt. 558

0.00125 milligrams per kilogram of body Subpart B—Specific New Animal Drugs For weight per day. Use in Animal Feeds (b) Tolerances. The tolerances for res- 558.55 Amprolium. idues of zeranol in edible tissues are: 558.58 Amprolium and ethopabate. (1) Cattle. A tolerance is not needed. 558.59 Apramycin. (2) Sheep. 20 parts per billion. 558.76 Bacitracin methylene disalicylate. (c) Related conditions of use. See 558.78 Bacitracin zinc. 558.95 Bambermycins. § 522.2680 of this chapter. 558.115 Carbadox. [40 FR 13942, Mar. 27, 1975, as amended at 54 558.128 Chlortetracycline. FR 31950, Aug. 3, 1989; 67 FR 6867, Feb. 14, 558.140 Chlortetracycline and sulfamethazine. 2002; 70 FR 15759, Mar. 29, 2005] 558.145 Chlortetracycline, procaine peni- cillin, and sulfamethazine. § 556.765 Zilpaterol. 558.175 Clopidol. (a) Acceptable daily intake (ADI). The 558.185 Coumaphos. ADI for total residues of zilpaterol is 558.195 Decoquinate. 558.198 Diclazuril. 0.083 micrograms per kilogram of body 558.205 Dichlorvos. weight per day. 558.235 Efrotomycin. (b) Tolerances—(1) Cattle—(i) Liver 558.248 Erythromycin. (the target tissue). The tolerance for 558.254 Famphur. zilpaterol freebase (the marker residue) 558.258 Fenbendazole. 558.261 Florfenicol. is 12 parts per billion (ppb). 558.265 Halofuginone hydrobromide. (ii) [Reserved] 558.274 Hygromycin B. (2) [Reserved] 558.295 Iodinated casein. 558.300 Ivermectin. [71 FR 53005, Sept. 8, 2006] 558.305 Laidlomycin. 558.311 Lasalocid. § 556.770 Zoalene. 558.325 Lincomycin. 558.340 Maduramicin. Tolerances are established for resi- 558.342 Melengestrol. dues of zoalene (3,5-dinitro-o- 558.348 Mibolerone. toluamide) and its metabolite 3-amino- 558.355 Monensin. 5-nitro-o-toluamide in food as follows: 558.360 Morantel tartrate. (a) In edible tissues of chickens: 558.363 Narasin. 558.364 Neomycin sulfate. (1) 6 parts per million in uncooked 558.365 Nequinate. liver and kidney. 558.366 Nicarbazin. (2) 3 parts per million in uncooked 558.369 Nitarsone. muscle tissue. 558.415 Novobiocin. (3) 2 parts per million in uncooked 558.430 Nystatin. 558.435 Oleandomycin. fat. 558.450 Oxytetracycline. (b) In edible tissues of turkeys: 3 558.455 Oxytetracycline and neomycin. parts per million in uncooked muscle 558.460 Penicillin. tissue and liver. 558.464 Poloxalene. 558.465 Poloxalene free-choice liquid Type C feed. PART 558—NEW ANIMAL DRUGS 558.485 Pyrantel. FOR USE IN ANIMAL FEEDS 558.500 Ractopamine. 558.515 Robenidine. Subpart A—General Provisions 558.550 Salinomycin. 558.555 Semduramicin. Sec. 558.575 Sulfadimethoxine, ormetoprim. 558.582 Sulfamerazine. 558.3 Definitions and general considerations 558.586 Sulfaquinoxaline. applicable to this part. 558.600 Thiabendazole. 558.4 Requirement of a medicated feed mill 558.612 Tiamulin. license. 558.618 Tilmicosin. 558.5 Requirements for liquid medicated 558.625 Tylosin. feed. 558.630 Tylosin and sulfamethazine. 558.6 Veterinary feed directive drugs. 558.635 Virginiamycin. 558.15 , nitrofuran, and sul- 558.665 Zilpaterol. fonamide drugs in the feed of animals. 558.680 Zoalene.

367

VerDate Sep<11>2014 16:01 May 14, 2015 Jkt 235075 PO 00000 Frm 00377 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31 lpowell on DSK54DXVN1OFR with $$_JOB